The first-ever human Phase I/II clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes has been launched by researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte Inc. The trial will test the safety and efficacy of the drug VC-01. Specially encapsulated stem cell derived cells will be implanted under the skin of patient’s where it is believed they will mature into pancreatic beta cells to produce insulin. ‘This is not yet a cure for diabetes’ said Professor Henry, the principle Investigator, the trial is designed to assess the basic safety and efficacy, ‘the hope nonetheless is that this approach will ultimately transform the way individuals with Type 1 diabetes manage their disease’. To read the article click here.